It formed a subsidiary in MA.
HEIDELBERG, GERMANY — Novaliq GmbH has formed a subsidiary called Novaliq Inc. in Cambridge, MA.
Novaliq GmbH describes itself as “a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology.”
The Cambridge office will be headed by Novaliq’s founder and current chief innovation officer, Bernhard Günther. Günther “ill build the new U.S. organization to leverage the advantages and the potential of the water-free EyeSol drug delivery technology and innovative products in the U.S.,” according to a press release.
“Over the past two years, Novaliq has gained significant momentum,” Günther said. “With the opening of our new U.S. subsidiary, we can better serve the important and growing U.S. eyecare market. I am excited to take on this new challenge and to lead the internationalization of the Novaliq group.”
In the U.S., Novaliq is currently pursuing two late-stage clinical trials in ophthalmology: one for topical CyclASol for the treatment of dry eye disease (DED), and the other to evaluate a compound called NOV03 at two different dosing regimens for evaporative dry eye disease.
“As a leader in DED with first and best-in-class products, we see our role in redefining how this disease is treated,” said Christian Roesky, CEO of Novaliq GmbH. “In the U.S., more than 16 million patients are diagnosed with DED; however, only approximately 10 percent are being treated. This significant gap is a clear indication that new DED therapies are needed. A strong presence in the United States will assist us to better serve this vital pharma market.”